Developer docs
API playgroundTry for free, no card

Search company profiles

Elevar Therapeutics

Full company profile

uuid0000o6i

Namestring
Elevar Therapeutics
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFort Lee, United States
HQ citystring
Fort Lee
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, targeted oncology therapy, FGFR2 inhibitors, rare cancer therapeutics, combination immunotherapy
Industry3 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAEAF
Digestive Oncology (GI Cancer Care)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Drug Sales
TypeOne Time License
Description

Pre-revenue biopharmaceutical company expecting commercialization of lirafugratinib following FDA approval. The company is preparing for commercialization and allocating significant resources to regulatory approval and market preparation.

koreatimes.co.kr
2Future Drug Combination Sales
TypeOne Time License
Description

Plan to resubmit drug application for rivoceranib and camrelizumab combination in January 2026 for hepatocellular carcinoma treatment following positive Phase 3 CARES-310 study results.

globenewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Elevar Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncology therapies for rare and underserved cancers. Its lead candidate, lirafugratinib, is an investigational FGFR2 inhibitor under FDA Priority Review for second-line treatment of cholangiocarcinoma with FGFR2 fusions or rearrangements (PDUFA date September 27, 2026). The company is also advancing the rivoceranib and camrelizumab combination (CARES-310) for unresectable hepatocellular carcinoma based on positive Phase 3 results.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 46.5% confirmed objective response rate in patients with FGFR2 fusion/rearrangement cholangiocarcinoma (ReFocus Phase 1/2 trial)
+3 more records
Product overview1 text field

Elevar Therapeutics is a pharmaceutical/biotechnology company focused on developing cancer therapeutics. The company's core product portfolio includes lirafugratinib, an investigational FGFR2 inhibitor currently under FDA Priority Review for second-line cholangiocarcinoma treatment, and the rivoceranib/camrelizumab combination therapy (CARES-310) for unresectable hepatocellular carcinoma. Elevar operates as a subsidiary of HLB, a Korean biotechnology firm, and is advancing clinical development across multiple cancer types.

Product and service2 records
1Lirafugratinib
CategoryOncology Pharmaceutical
2Rivoceranib + Camrelizumab Combination (CARES-310)
CategoryOncology Pharmaceutical
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Samsung Medical Center in Seoul is a clinical trial site for the ReFocus202 Phase 2 study evaluating lirafugratinib for non-cholangiocarcinoma solid tumors with FGFR2 fusion or rearrangement.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Moffitt Cancer Center in Tampa is a clinical trial site for the ReFocus202 Phase 2 study evaluating lirafugratinib for non-cholangiocarcinoma solid tumors with FGFR2 fusion or rearrangement.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Roche/Genentech markets atezolizumab + bevacizumab (Tecentriq + Avastin), the current standard of care in first-line uHCC. Comparable as the dominant incumbent whose immunotherapy combination defines the HCC treatment landscape.

TypeDirect peer
Description

Incyte markets pemigatinib (Pemazyre), an FGFR inhibitor approved for FGFR2-fusion cholangiocarcinoma. It is the most directly comparable competitor in the same indication that Elevar's lirafugratinib targets, with established commercial infrastructure in second-line CCA.

TypeEmerging player
Description

Erasca is a clinical-stage precision oncology company with FGFR pathway programs. Comparable as a small-cap, kinase-inhibitor-focused oncology developer pursuing FGFR-driven cancers.

TypeBroad incumbent
Description

Exelixis markets cabozantinib (Cabometyx) in hepatocellular carcinoma, including settings where Elevar's rivoceranib+camrelizumab combination competes. Comparable as an established oncology company in the HCC competitive landscape.

TypeBroad incumbent
Description

AstraZeneca markets the STRIDE regimen (durvalumab + tremelimumab) in uHCC, a direct competitive regimen to the CARES-310 combination. Comparable as a global oncology incumbent whose HCC franchise shapes the market Elevar is entering.

TypeEmerging player
Description

Relay Therapeutics is a clinical-stage precision oncology company developing FGFR2-selective inhibitors. Comparable as a targeted-kinase-inhibitor oncology developer with overlapping FGFR2 biology.

TypeRegional player
Description

Jazz Pharmaceuticals is a specialty biopharma with a strong oncology and rare-disease commercial footprint in the U.S. and Europe. Comparable as a specialty/rare-disease commercial model against which Elevar's U.S. field-sales and specialty distribution strategy will be benchmarked.

8HUTCHMED
TypeDirect peer
Description

HUTCHMED is an Asia-headquartered biopharma developing oncology therapeutics, including surufatinib, with global commercialization strategy. Directly comparable to Elevar as an Asian-originated biopharma advancing innovative oncology drugs into the U.S. market.

TypeDirect peer
Description

Taiho Oncology markets futibatinib (Lytgobi), another FDA-approved FGFR inhibitor for FGFR2-fusion cholangiocarcinoma. Direct head-to-head competitor to lirafugratinib in the same second-line CCA indication.

TypeEmerging player
Description

QED Therapeutics, a BridgeBio subsidiary, developed infigratinib, an earlier FGFR inhibitor in cholangiocarcinoma. Comparable as an FGFR-focused oncology developer with overlapping target indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Elevar Therapeutics

Oncology Pharmaceuticalselevartherapeutics.com

Elevar Therapeutics firmographics

Firmographics
Name
Elevar Therapeutics
Website
https://elevartherapeutics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Elevar Therapeutics industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAEAF
Digestive Oncology (GI Cancer Care)

Keywords

  • Clinical-stage biopharmaceutical
  • Targeted oncology therapy
  • FGFR2 inhibitors
  • Rare cancer therapeutics
  • Combination immunotherapy

Where Elevar Therapeutics is headquartered

Location

Headquarters

HQ city
Fort Lee
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Elevar Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Drug Sales: Pre-revenue biopharmaceutical company expecting commercialization of lirafugratinib following FDA approval. The company is preparing for commercialization and allocating significant resources to regulatory approval and market preparation.
  2. Future Drug Combination Sales: Plan to resubmit drug application for rivoceranib and camrelizumab combination in January 2026 for hepatocellular carcinoma treatment following positive Phase 3 CARES-310 study results.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Elevar Therapeutics product offering

Product offering

Core offering

Elevar Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncology therapies for rare and underserved cancers. Its lead candidate, lirafugratinib, is an investigational FGFR2 inhibitor under FDA Priority Review for second-line treatment of cholangiocarcinoma with FGFR2 fusions or rearrangements (PDUFA date September 27, 2026). The company is also advancing the rivoceranib and camrelizumab combination (CARES-310) for unresectable hepatocellular carcinoma based on positive Phase 3 results.

Product overview

Elevar Therapeutics is a pharmaceutical/biotechnology company focused on developing cancer therapeutics. The company's core product portfolio includes lirafugratinib, an investigational FGFR2 inhibitor currently under FDA Priority Review for second-line cholangiocarcinoma treatment, and the rivoceranib/camrelizumab combination therapy (CARES-310) for unresectable hepatocellular carcinoma. Elevar operates as a subsidiary of HLB, a Korean biotechnology firm, and is advancing clinical development across multiple cancer types.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lirafugratinib
  • Rivoceranib + Camrelizumab Combination (CARES-310)

Quantifiable outcome

  • 46.5% confirmed objective response rate in patients with FGFR2 fusion/rearrangement cholangiocarcinoma (ReFocus Phase 1/2 trial)
  • +3 more outcomes

Companies that use Elevar Therapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Elevar Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Elevar Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Samsung Medical CentercoreStrategic or Co-development PartnerSamsung Medical Center in Seoul is a clinical trial site for the ReFocus202 Phase 2 study evaluating lirafugratinib for non-cholangiocarcinoma solid tumors with FGFR2 fusion or rearrangement.
  • Moffitt Cancer CentercoreStrategic or Co-development PartnerMoffitt Cancer Center in Tampa is a clinical trial site for the ReFocus202 Phase 2 study evaluating lirafugratinib for non-cholangiocarcinoma solid tumors with FGFR2 fusion or rearrangement.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Elevar Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Roche / Genentech: Roche/Genentech markets atezolizumab + bevacizumab (Tecentriq + Avastin), the current standard of care in first-line uHCC. Comparable as the dominant incumbent whose immunotherapy combination defines the HCC treatment landscape.
  • Exelixis: Exelixis markets cabozantinib (Cabometyx) in hepatocellular carcinoma, including settings where Elevar's rivoceranib+camrelizumab combination competes. Comparable as an established oncology company in the HCC competitive landscape.
  • AstraZeneca: AstraZeneca markets the STRIDE regimen (durvalumab + tremelimumab) in uHCC, a direct competitive regimen to the CARES-310 combination. Comparable as a global oncology incumbent whose HCC franchise shapes the market Elevar is entering.

Direct peers

  • Incyte Corporation: Incyte markets pemigatinib (Pemazyre), an FGFR inhibitor approved for FGFR2-fusion cholangiocarcinoma. It is the most directly comparable competitor in the same indication that Elevar's lirafugratinib targets, with established commercial infrastructure in second-line CCA.
  • HUTCHMED: HUTCHMED is an Asia-headquartered biopharma developing oncology therapeutics, including surufatinib, with global commercialization strategy. Directly comparable to Elevar as an Asian-originated biopharma advancing innovative oncology drugs into the U.S. market.
  • Taiho Oncology: Taiho Oncology markets futibatinib (Lytgobi), another FDA-approved FGFR inhibitor for FGFR2-fusion cholangiocarcinoma. Direct head-to-head competitor to lirafugratinib in the same second-line CCA indication.

Emerging players

  • Erasca: Erasca is a clinical-stage precision oncology company with FGFR pathway programs. Comparable as a small-cap, kinase-inhibitor-focused oncology developer pursuing FGFR-driven cancers.
  • Relay Therapeutics: Relay Therapeutics is a clinical-stage precision oncology company developing FGFR2-selective inhibitors. Comparable as a targeted-kinase-inhibitor oncology developer with overlapping FGFR2 biology.
  • QED Therapeutics (BridgeBio): QED Therapeutics, a BridgeBio subsidiary, developed infigratinib, an earlier FGFR inhibitor in cholangiocarcinoma. Comparable as an FGFR-focused oncology developer with overlapping target indication.

Regional players

  • Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty biopharma with a strong oncology and rare-disease commercial footprint in the U.S. and Europe. Comparable as a specialty/rare-disease commercial model against which Elevar's U.S. field-sales and specialty distribution strategy will be benchmarked.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Elevar Therapeutics social profiles

Digital presence

Elevar Therapeutics compliance and trust

Trust signal

Compliance3 records

Elevar Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Elevar Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Elevar Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Elevar Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elevar Therapeutics

What does Elevar Therapeutics do?

Elevar Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncology therapies for rare and underserved cancers. Its lead candidate, lirafugratinib, is an investigational FGFR2 inhibitor under FDA Priority Review for second-line treatment of cholangiocarcinoma with FGFR2 fusions or rearrangements (PDUFA date September 27, 2026). The company is also advancing the rivoceranib and camrelizumab combination (CARES-310) for unresectable hepatocellular carcinoma based on positive Phase 3 results.

Is Elevar Therapeutics a public or private company?

Elevar Therapeutics is a private company. It is classified as corporate owned and is currently operating.

When was Elevar Therapeutics founded?

Elevar Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is Elevar Therapeutics based?

Elevar Therapeutics is headquartered in Fort Lee, United States, in the North America region.

How does Elevar Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Drug Sales are the primary driver. The others are future Drug Combination Sales.

Who are Elevar Therapeutics's main competitors?

Broad incumbents on record are Roche / Genentech, Exelixis and AstraZeneca. Direct peers are Incyte Corporation, HUTCHMED and Taiho Oncology. Emerging players are Erasca, Relay Therapeutics and QED Therapeutics (BridgeBio). Jazz Pharmaceuticals is listed as a regional player.

Does Elevar Therapeutics have an API?

No public API is recorded for Elevar Therapeutics.

What industry is Elevar Therapeutics in?

Elevar Therapeutics's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialElevar Therapeutics Announces Lirafugratinib (Lyrfigtu) Added To NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines) As Second-Line Therapy For Cholangiocarcinoma With FGFR2 Fusion Or Other RearrangementElevar Therapeutics announced FDA approval of lirafugratinib (Lyrfigtu) for cholangiocarcinoma with FGFR2 fusion or rearrangement, with the drug added to NCCN guidelines as second-line therapy. The drug is expected to be available in the U.S. by Q4 2026, and the Phase 1/2 ReFocus trial (NCT04526106) supported the approval.GlobeNewswireElevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular CarcinomaElevar Therapeutics resubmitted an NDA to the FDA for camrelizumab plus rivoceranib as first-line treatment for unresectable or metastatic hepatocellular carcinoma. The combination achieved a median overall survival of 23.8 months versus 15.2 months with sorafenib in the CARES-310 study. The company expects continued FDA review.NaverLirafugratinib: What the EMA's Review Means for European Cancer Treatment in 2026Elevar Therapeutics received EMA notification that the review of Lirafugratinib for bile duct cancer has begun. The drug received full FDA approval on September 23 and is planned for U.S. launch in Q4. Elevar is also pursuing expansion to other solid tumors.NaverHLB 담관암 신약 '리라푸그라티닙', 유럽 허가 본심사 착수HLB's US subsidiary Elevar Therapeutics received EMA notification that review of lirafugratinib's marketing authorization application began. The drug, approved by the FDA as Lyrfigu in the US, is planned for US launch in Q4 and European market entry. Elevar is also developing the drug for other solid tumors.Nate[장성훈의 신약개발 서랍장④]"좌완 파이어볼러는 지옥에서라도 데려와라" : 네이트 뉴스A regulatory consultant argues that recruiting the right talent is critical in drug development, citing his experience at Elevar Therapeutics where he hired a former FDA reviewer. The hire helped navigate regulatory submissions for two drugs, including ribociclib and liraglutide, and the consultant emphasizes that such talent is rare and must be retained.Endpoints NewsElevar wins first FDA approval with second-line drug for bile duct cancerThe FDA approved Elevar Therapeutics' Lyrfigtu as a second-line treatment for bile duct cancer, affecting about 8,000 Americans. The approval marks the first FDA approval for this second-line drug in this indication.FiercePharmaElevar wins FDA nod for bile duct cancer drug Lyrfigtu, a first for a Korean firmThe FDA approved Elevar Therapeutics' Lyrfigtu for bile duct cancer with FGFR2 fusion, marking the first novel cancer drug from a Korean firm. The drug showed a 46% objective response rate and 11.8-month median duration in a trial. Elevar expects U.S. patient access this year and has filed with the EMA.BioSpaceElevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment OptionElevar Therapeutics announced FDA approval of Lyrfigtu (lirafugratinib) for cholangiocarcinoma with FGFR2 fusion or rearrangement. The drug showed a 46% confirmed objective response rate and 11.8-month median duration of response in the ReFocus trial. It is expected to be available in the U.S. by Q4 2026.The Pharma LetterFDA approves Elevar’s lirafugratinibThe FDA approved Elevar Therapeutics' lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene fusion or rearrangement. The approval provides a second-line treatment option, according to Elevar CEO Dong-Gun Kim, who said the company is focused on getting the therapy to doctors and patients quickly.FiercePharmaHow 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approvalHengrui Pharma and Elevar Therapeutics received their third FDA rejection for the camrelizumab and rivoceranib liver cancer combination, with the agency citing manufacturing facility deficiencies in a Complete Response Letter. While the Jinqiao facility's issues were resolved (earning VAI classification), a second Hengrui plant in Lianyungang received a Form 483 with nine observations related to aseptic processing and quality control during a June-July 2026 inspection, creating a separate obstacle to approval. The companies plan to address the Dongjin facility issues and are considering using a U.S. contract manufacturing organization as part of a two-track strategy to secure future approvals.